Treating the dementia of Iris with a cholinesterase inhibitor
โ Scribed by Robin Jacoby
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 19 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0885-6230
- DOI
- 10.1002/gps.904
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
fact may be ascribed to a primarily biological origin of the disease, not correlated with other possible causative events (e.g. chronic somatic diseases). On the other hand, in patients with reactive depressive symptoms a higher prevalence of somatic dysfunction (e.g. number of diseases, Charlson In
the range. Overall, it was found that the prevalence of substance misuse in the elderly in-patient population was lower than in the younger population, and a little lower than expected. There may be several reasons for this. Firstly, this study was not speciยฎcally designed for the elderly population
## Abstract ## Objective To compare efficacy of different cholinesterase inhibitors (ChEIs) for treating patients with dementia with Lewy bodies (DLB). ## Design Retrospective comparison of three independent clinical studies of ChEI treatment using donepezil, galantamine or rivastigmine in patie
## Abstract ## Objective To assess the cost effectiveness of cholinesterase inhibitor (ChEI) treatment in patients with Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB). ## Method We used 4โmonth open label followโup data from routine memory clinic patients. There were 852 patients w
An increasing number of elderly people result in increased social and economical impact of dementia, particularly its most common form Alzheimer's disease (AD). Dementia itself consists of a wide spectrum of disease, ranging from the mild cognitive impairment that progresses through several clinical